发布求助
文献互助 智能选刊 最新文献

Skin therapy letter最新文献

筛选
英文 中文
Antibiotic Resistance in Dermatology Part 2: Combating Resistance. 皮肤病学抗生素耐药性第2部分:对抗耐药性。
Skin therapy letter Pub Date : 2023-03-01
Austinn C Miller, Susuana Adjei, Laurie A Temiz, Sonali Batta, Stephen K Tyring
{"title":"Antibiotic Resistance in Dermatology Part 2: Combating Resistance.","authors":"Austinn C Miller,&nbsp;Susuana Adjei,&nbsp;Laurie A Temiz,&nbsp;Sonali Batta,&nbsp;Stephen K Tyring","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Virtually any antibiotic can be used in dermatology given the broad range of conditions treated. With the widespread use of antibiotics and the rapid emergence of resistant organisms, it is important to understand how dermatologists can combat this issue.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"28 2","pages":"6-9"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9309597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chlormethine Gel for the Treatment of Mycosis Fungoides (Cutaneous T-cell Lymphoma) in Canada. 氯甲基凝胶治疗蕈样真菌病(皮肤t细胞淋巴瘤)在加拿大。
Skin therapy letter Pub Date : 2023-03-01
Robert Gniadecki, Emilia Paron
{"title":"Chlormethine Gel for the Treatment of Mycosis Fungoides (Cutaneous T-cell Lymphoma) in Canada.","authors":"Robert Gniadecki,&nbsp;Emilia Paron","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL), representing almost 50% of all lymphomas arising in the skin. There is an unmet need in the treatment of MF in Canada, as current available therapies for early-stage MF are limited, without topical agents previously indicated. Chlormethine gel is a topical antineoplastic agent with phase II clinical trial and real-world data demonstrating safety and efficacy as a treatment option for adults with MF. Skin-related side effects such as dermatitis can be managed through appropriate strategies. The use of chlormethine gel can be considered for patients with stage IA and IB MF-CTCL as it provides an easily administered, skin-directed treatment option that fills an unmet need in Canada.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"28 2","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9309598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults. 曲洛单抗治疗成人中重度特应性皮炎。
Skin therapy letter Pub Date : 2023-01-01
Abrahim Abduelmula, Brian D Rankin, Asfandyar Mufti, Jensen Yeung, Vimal H Prajapati
{"title":"Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults.","authors":"Abrahim Abduelmula,&nbsp;Brian D Rankin,&nbsp;Asfandyar Mufti,&nbsp;Jensen Yeung,&nbsp;Vimal H Prajapati","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a common, chronic, recurrent, immune-mediated inflammatory skin disease. Targeted treatment options remain limited. Tralokinumab (Adtralza®) is a promising, new systemic therapy that inhibits interleukin-13. It was recently approved by Health Canada and the US FDA for the treatment of moderate-to-severe AD in adults and may be used alone or with topical corticosteroids. Herein, we review the efficacy and safety of tralokinumab in adults, as demonstrated in clinical trials.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"28 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9123427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antibiotic Resistance in Dermatology Part 1: Mechanisms of Resistance. 皮肤病学中的抗生素耐药:耐药机制。
Skin therapy letter Pub Date : 2023-01-01
Austinn C. Miller, Susuana Adjei, Laurie A. Temiz, Stephen K. Tyring
{"title":"Antibiotic Resistance in Dermatology Part 1: Mechanisms of Resistance.","authors":"Austinn C. Miller,&nbsp;Susuana Adjei,&nbsp;Laurie A. Temiz,&nbsp;Stephen K. Tyring","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Virtually any antibiotic can be used in dermatology given the broad range of conditions treated. With the widespread use of antibiotics and the rapid emergence of resistant organisms, it is important to understand the mechanisms at play that contribute to resistance.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"28 1","pages":"7-10"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9123428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis 选择性抑制TYK2治疗中重度慢性斑块型银屑病
Skin therapy letter Pub Date : 2022-11-01
Melinda J Gooderham, H Chih-Ho Hong, Ivan V Litvinov
{"title":"Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis","authors":"Melinda J Gooderham,&nbsp;H Chih-Ho Hong,&nbsp;Ivan V Litvinov","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Moderate to severe chronic plaque psoriasis may be difficult to control using current therapies, which has led to development of a novel class of therapy, selective tyrosine kinase 2 (TYK2) inhibitors, to address this unmet need. Oral deucravacitinib is a first-inclass selective TYK2 inhibitor, which has shown efficacy in moderate to severe chronic plaque psoriasis from two phase III pivotal trials (POETYK PSO-1 and PSO-2), whereby response rates were significantly higher with deucravacitinib vs. placebo or apremilast for Psoriasis Area Severity Index (PASI) 75 and static Physician's Global Assessment (sPGA) 0/1. Deucravacitinib was generally well tolerated and safe compared to placebo and apremilast. Although deucravacitinib is a type of Janus kinase (JAK) inhibitor, it only blocks specific cytokine-driven responses, potentially reducing off-target effects more commonly associated with other JAK inhibitors on the market. Incidence rates of serious adverse events, such as serious infections, malignancies, thrombosis, cardiovascular events, creatinine kinase elevation, hematologic changes, and lipid profile abnormalities were absent or low.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"27 6","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35348223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acne Scars: An Update on Management 痤疮疤痕:管理的最新进展
Skin therapy letter Pub Date : 2022-11-01
Abdulhadi Jfri, Ali Alajmi, Mohammad Alazemi, Malika A Ladha
{"title":"Acne Scars: An Update on Management","authors":"Abdulhadi Jfri,&nbsp;Ali Alajmi,&nbsp;Mohammad Alazemi,&nbsp;Malika A Ladha","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Acne vulgaris is a troubling skin disease known to have both physiologic and psychological effects on patients. Acne scars, a frequent complication, can further impact patients' quality of life. Scars result from an impairment in the healing process. Acne scars can be categorized as follows: atrophic scars (including ice pick, rolling, boxcar subtypes) and trophic (including hypertrophic and keloid scars), the latter being less common. Though various treatment approaches have been suggested, there is a lack of high-quality evidence on effective, type-specific acne scar approaches. Herein, we aim to review the current evidence for treating various acne scars.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"27 6","pages":"6-9"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35346629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extracorporeal Photopheresis and Its Use in Clinical Dermatology in Canada 体外光术及其在加拿大临床皮肤病学中的应用
Skin therapy letter Pub Date : 2022-09-01
François Lagacé, Elena Netchiporouk, Irina Turchin, Wayne Gulliver, Jan Dutz, Mark G Kirchhof, Popradi Popradi, Robert Gniadecki, Charles Lynde, Ivan V Litvinov
{"title":"Extracorporeal Photopheresis and Its Use in Clinical Dermatology in Canada","authors":"François Lagacé,&nbsp;Elena Netchiporouk,&nbsp;Irina Turchin,&nbsp;Wayne Gulliver,&nbsp;Jan Dutz,&nbsp;Mark G Kirchhof,&nbsp;Popradi Popradi,&nbsp;Robert Gniadecki,&nbsp;Charles Lynde,&nbsp;Ivan V Litvinov","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Extracorporeal photopheresis (ECP) is an immunomodulatory therapy that has been used for over 35 years to treat numerous conditions. ECP was initially approved by the US FDA in 1988 for the treatment of Sézary syndrome, a leukemic form of cutaneous T-cell lymphoma (CTCL). Although CTCL remains the only FDA-approved indication, ECP has since been used off-label for numerous other conditions, including graft-versus-host disease (GvHD), systemic sclerosis, autoimmune bullous dermatoses, Crohn's disease, and prevention of solid organ transplant rejection. In Canada, ECP is mainly used to treat CTCL, acute and chronic GvHD, and in some instances systemic sclerosis. Herein, we review the current concepts regarding ECP mechanism of action, treatment considerations and protocols, and efficacy.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"27 5","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35210368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toxic Epidermal Necrolysis: A Review of Past and Present Therapeutic Approaches 中毒性表皮坏死松解:回顾过去和现在的治疗方法
Skin therapy letter Pub Date : 2022-09-01
Neha Singh, Mariana Phillips
{"title":"Toxic Epidermal Necrolysis: A Review of Past and Present Therapeutic Approaches","authors":"Neha Singh,&nbsp;Mariana Phillips","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Toxic epidermal necrolysis (TEN) is an immune mediated, severe cutaneous adverse drug reaction characterized by epidermal detachment affecting greater than 30% body surface area. The mortality rate of TEN exceeds 20% and is usually caused by infection and respiratory compromise. Withdrawal of the causative drug, supportive care, and adjuvant therapy improve prognosis. Over the past decade, randomized controlled trials and meta-analyses have supported a role for cyclosporine, tumor necrosis factor alpha inhibitors, and combination therapy with intravenous immune globulin and corticosteroids. This review summarizes the medical management of TEN in adult patients.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"27 5","pages":"7-13"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35258629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tirbanibulin for the Treatment of Actinic Keratosis: A Review 蒂巴尼布林治疗光化性角化病的研究进展
Skin therapy letter Pub Date : 2022-07-01
Austinn C Miller, Susuana Adjei, Laurie A Temiz, Stephen K Tyring
{"title":"Tirbanibulin for the Treatment of Actinic Keratosis: A Review","authors":"Austinn C Miller, Susuana Adjei, Laurie A Temiz, Stephen K Tyring","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Actinic keratosis (AK) is a common precancerous condition found on chronically sun-damaged skin, particularly on the face, scalp, arms, and legs. Early and effective treatment of AKs is important to prevent progression to squamous cell carcinoma. Many topical treatments for AKs are often limited because of poor tolerability, prolonged treatment duration, and reduced adherence. Tirbanibulin 1% ointment, a new topical field therapy for AKs, reduces these issues. It requires a consecutive 5-day application period and is effective, demonstrating complete (100%) clearance of AK lesions in 49% of patients, partial (>75%) clearance in 72%, and a median reduction in lesion count of 87.5% while exhibiting a favorable safety profile, mild adverse events, improved tolerability, and long-term results.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"27 4","pages":"4-7"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40523157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tazarotene Lotion 0.045% for the Treatment of Acne 0.045%他沙罗汀洗剂治疗痤疮
Skin therapy letter Pub Date : 2022-07-01
Catherine Zip
{"title":"Tazarotene Lotion 0.045% for the Treatment of Acne","authors":"Catherine Zip","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Topical retinoids are recommended as first line therapy for the treatment of acne. Despite this recommendation, topical retinoids are underutilized, in part because of their tendency to cause cutaneous irritation. Tazarotene 0.045% lotion was developed using polymeric emulsion technology to provide an effective, well tolerated topical retinoid for the treatment of acne.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"27 4","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40620490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信